Results 1 to 10 of about 5,084 (185)

A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex [PDF]

BMC Immunology, 2020
Background The use of anti-B cell based therapies in immune-mediated diseases targeting general B cell markers or molecules important for B cell function has increased the clinical needs of monitoring B cell subpopulations.
Susanne Axelsson, Anders Magnuson, Anna Lange, Aseel Alshamari, Elisabeth Hultgren Hörnquist, Olof Hultgren   +5 more
doaj   +7 more sources

B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer [PDF]

Frontiers in Immunology
BackgroundImmunotherapies targeting the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) have shown great promise for a subset of patients with non-small cell lung cancer (NSCLC).
Yang Zhang, Yang Zhang, Yang Yang, Yang Yang, Yuanyuan Zeng, Yuanyuan Zeng, Qiuxia Qu, Dan Shen, Chuanyong Mu, Wei Lei, Meiqin Su, Jingyu Mao, Lirong Gao, Zeyi Liu, Zeyi Liu, Cheng Chen, Jian-an Huang, Jian-an Huang   +17 more
doaj   +5 more sources

The synergism of B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) attenuated acute T-cell mediated rejection and prolonged renal graft survival. [PDF]

Transl Androl Urol, 2020
Acute T-cell mediated rejection (TCMR) continues to be a major problem in the area of kidney transplantation. The B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) were recently found costimulatory molecules. The research aims to explore the inhibitory synergism of BTLA and CTLA-4 in TCMR.We investigated the ...
Zhang H, Wang Z, Zhang J, Zhang X, Gui Z, Sun L, Yang H, Tan R, Gu M.   +8 more
europepmc   +6 more sources

The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases

Frontiers in Immunology, 2021
B and T lymphocyte attenuator (BTLA), an immunomodulatory molecule widely expressed on the surface of immune cells, can influence various signaling pathways and negatively regulate the activation and proliferation of immune cells by binding to its ligand
Zheng Zheng
exaly   +4 more sources

Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma

Frontiers in Oncology, 2021
B and T lymphocyte attenuator (BTLA) is a newly identified immune checkpoint molecular belonging to the CD28 immunoglobulin superfamily. However, the expression and clinical value of BTLA in skin cutaneous melanoma (SKCM) has not been widely ...
Xiaohua Zhang, Xubin Dong, Jingjing Song   +2 more
exaly   +4 more sources

Association between B and T lymphocyte attenuator/herpes virus entry mediator immunoregulatory axis and outcome prediction in a mixed critically ill population. [PDF]

Sci Rep
B and T lymphocyte attenuator (BTLA) and herpes virus entry mediator (HVEM) are emerging immune checkpoint molecules implicated in immune dysregulation during critical illness.
Kokkoris S, Theodorou E, Lotsios NS, Keskinidou C, Vrettou CS, Poupouzas G, Issaris V, Premetis I, Kotanidou A, Dimopoulou I, Vassiliou AG.   +10 more
europepmc   +2 more sources

Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy Combinations. [PDF]

JCO Precis Oncol
PURPOSE Cotargetable immune pathways for available immune checkpoint inhibitors (ICIs) may mediate response and mitigate resistance. Immune profiling may provide insights into potential immunotherapy combinations and guide ongoing clinical trials.
Nishizaki D, Choi S, Pandya C, Lee S, Pabla S, DePietro P, Jensen TJ, Kurzrock R, Kato S.   +8 more
europepmc   +2 more sources

Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia

Blood, 2015
Abstract Background. The genetic factors that contribute to dissemination and relapse in aggressive lymphomas and acute lymphoblastic leukemia (ALL) are incompletely defined. We tested the hypothesis that shared molecular pathways contribute to drug resistance and metastasis in three distinct types of lymphoid neoplasms: large B-cell ...
Huimin Geng, Zhengshan Chen, Shawn Anderson, Eleanor Fraser, Ming Lu, Chen Lingjing, Colin Collins, Muschen Markus, James L. Rubenstein   +8 more
openaire   +2 more sources

BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy [PDF]

Pharmaceuticals
B and T lymphocyte attenuator (BTLA) is a unique co-inhibitory receptor of the CD28 immunoglobulin superfamily that exhibits dual regulatory functions in immune activation and tolerance.
Ming-Cheng Chang, Wan-Chi Lee, Yi-Jou Tai, Ying-Cheng Chiang   +3 more
doaj   +2 more sources

Elevated BTLA Expression Correlates with an Immunosuppressive Microenvironment and Defines Dysfunctional Circulating T Cells in Human Glioblastoma [PDF]

Medical Sciences
Background: Successful translation of cancer immunotherapy is underscored by the efficacy of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of various malignancies.
Sanaa Souat, Khadija El Azhary, Sara Bourdoukh, Abdou-samad Kone, Ahmed Qandouci, Zakia Harmak, Khalil Choukri, Abdelhakim Lakhdar, Abdallah Badou   +8 more
doaj   +2 more sources